GO:0032354Ontology (GO BP)GO biological process · ~16 member genes
Q-omics provides the Response to follicle-stimulating hormone (GO:0032354) pathway profile, scoring each patient from the combined activity of its roughly 16 member genes. Pathway activity is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 14, with the highest sampling consensus in BLCA. Additionally, pathway RNA activity shows 33,661 significant cross-omics associations, again with the highest sampling consensus in STAD. Together, these results highlight LIHC, BLCA, and STAD as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Response to follicle-stimulating hormone survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Response to follicle-stimulating hormone activity shows favorable associations in LIHC and KIRC, but unfavorable associations in KIRP, MESO, PAAD and STAD. In the LIHC Kaplan–Meier curve the low-activity group declines faster, consistent with the favorable association (log-rank p < 0.001). LIHC ranks highest by sampling consensus for Response to follicle-stimulating hormone.
This table summarizes Response to follicle-stimulating hormone tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 14 cancer types, while mass-spec protein activity shows differences in 5. The strongest signals are in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows higher tumor activity across BLCA, LUAD and LUSC and lower tumor activity in KICH, KIRP and BRCA. In the BLCA box plot, tumor samples show higher pathway activity than matched normal samples (log2 FC = +0.072, t-test p < 0.001).
This table shows molecular features associated with Response to follicle-stimulating hormone pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in STAD. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in PANCREAS.
